Program
asimadoline
Also written as “Asimadoline”.
Its studies are mostly in Hot Flashes · Pruritus · Diarrhea · Ileus · Irritable Bowel Syndrome, led by Tioga Pharmaceuticals.
Furthest: phase 3, since Apr 6, 20106 company-led studies, 1 open or runningNext primary completion: Oct 31, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Tioga Pharmaceuticals | 61 open or running | phase 3since Apr 6, 2010 | Feb 27, 2007 | Oct 31, 2027phase 2 · NCT07042516 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 27, 2007First study: phase 2 study in Post-Operative IleusFirst studyNCT00443040 · 35 enrolled · United States
- Mar 29, 2007Phase 2 study in Irritable Bowel SyndromeNCT00454688 · 596 enrolled · United States
- Apr 6, 2010Phase 3 study in Diarrhea Predominant Irritable Bowel SyndromeNCT01100684 · 611 enrolled · United States
- Jun 13, 2011Phase 1 study in HealthyNCT01380561 · 6 enrolled · United States
- Feb 10, 2015Phase 2 study in PruritusNCT02475447 · 249 enrolled · United States
- Jun 19, 2025Phase 2 study in Hot FlashesNCT07042516 · 120 planned · United States
Ahead
- Oct 31, 2027Primary completion: phase 2 study in Hot FlashesNCT07042516
TargetBeta
OPRK1 →read by rule
“Kappa opioid receptor agonist”ChEMBL 37, by rule
Other programs on OPRK1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Naltrexonerule | orexigen-therapeutics-inc | phase 4 | 42 |
| nalmefenerule | H. Lundbeck | phase 4 | 20 |
| Nalbuphinerule | Trevi Therapeutics | phase 4 | 20 |
| cebranopadolrule | Tris Pharma | phase 3 | 18 |
| Aticaprantrule | Johnson & Johnson | phase 3 | 13 |
| nalfurafinerule | toray-industries-inc | phase 3 | 9 |
| icalcaprant | AbbVie | phase 2 | 6 |
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07042516Hot Flashes · United States | 2 | Recruiting | Oct 31, 2027 | 120 |
| NCT02475447Pruritus · United States | 2 | Completed | Jun 2017 | 249 |
| NCT01380561Healthy · United States | 1 | Completed | Jul 2011 | 6 |
| NCT01100684Diarrhea Predominant Irritable Bowel Syndrome · United States | 3 | Completed | Jun 2013 | 611 |
| NCT00454688Irritable Bowel Syndrome · United States | 2 | Completed | Nov 2007 | 596 |
| NCT00443040Post-Operative Ileus · United States | 2 | Terminated | Feb 2008 | 35 |
How it is read
Names in the registry
- “Asimadoline”, 5 entries
- “asimadoline”, 1 entry
Conditions, from the studies’ own filings
- Hot Flashes, 1 study
- Pruritus, 1 study
- Diarrhea, 1 study
- Ileus, 1 study
- Irritable Bowel Syndrome, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.